- Home
- MYGN vs BE Comparison
MYGN vs BE Comparison
Compare MYGN & BE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BE
- Stock Information
- Founded
- MYGN 1991
- BE 2001
- Country
- MYGN United States
- BE United States
- Employees
- MYGN N/A
- BE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BE Industrial Machinery/Components
- Sector
- MYGN Health Care
- BE Energy
- Exchange
- MYGN Nasdaq
- BE Nasdaq
- Market Cap
- MYGN 2.0B
- BE 2.3B
- IPO Year
- MYGN 1995
- BE 2018
- Fundamental
- Price
- MYGN $13.36
- BE $24.12
- Analyst Decision
- MYGN Hold
- BE Buy
- Analyst Count
- MYGN 12
- BE 19
- Target Price
- MYGN $23.92
- BE $23.00
- AVG Volume (30 Days)
- MYGN 942.4K
- BE 7.6M
- Earning Date
- MYGN 11-07-2024
- BE 02-13-2025
- Dividend Yield
- MYGN N/A
- BE N/A
- EPS Growth
- MYGN N/A
- BE N/A
- EPS
- MYGN N/A
- BE N/A
- Revenue
- MYGN $823,600,000.00
- BE $1,258,379,000.00
- Revenue This Year
- MYGN $13.82
- BE $9.34
- Revenue Next Year
- MYGN $4.59
- BE $19.20
- P/E Ratio
- MYGN N/A
- BE N/A
- Revenue Growth
- MYGN 12.15
- BE N/A
- 52 Week Low
- MYGN $12.87
- BE $8.41
- 52 Week High
- MYGN $29.30
- BE $28.70
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- BE 55.30
- Support Level
- MYGN $12.87
- BE $21.91
- Resistance Level
- MYGN $15.44
- BE $27.06
- Average True Range (ATR)
- MYGN 0.84
- BE 2.03
- MACD
- MYGN -0.02
- BE -0.79
- Stochastic Oscillator
- MYGN 12.37
- BE 33.61
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and South Korea.